NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
03/10/2019
Voltar para busca
Dado oficial do USPTO
INDUS PHARMACEUTICALS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
INDUS PHARMACEUTICALS
ST13
US500000078596173Classe
42
Pedido
78596173
Registro
3674488
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
50
Atualização mais recente
03/10/2019
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
42
Data de depósito
28/03/2005
Data de registro
25/08/2009
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
03/10/2019
Última transação
03/10/2019
Escritório responsável
United States Patent and Trademark Office
Código da situação
800
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
31/03/2006
Primeiro uso no comércio
31/03/2006
Código do desenho
4
Tipo de titular
03
Localização do titular
Andover, MA, US
Examinador
BHANOT, KAPIL KUMAR
Unidade examinadora
L80
Localização atual
GENERIC WEB UPDATE
Titulares e representantes
Titulares
IndUS Pharmaceuticals, Inc.
Representantes
H. Straat Tenney Locke Lord LLP
Classificação técnica
Classes Nice
Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 42
pharmaceutical drug development services of pharmaceutical products intended for the treatment of infectious diseases, namely, bacterial, fungal, parasitic and viral infections; pharmaceutical drug development services of pharmaceutical products intended for the treatment of neoplastic disorders, namely, hematologic cancer disorders and solid tumors; pharmaceutical drug development services of pharmaceutical products intended for the treatment of autoimmune disorders, namely, diabetes, arthritis, psoriasis, bone marrow and organ transplantation and immunosuppression; pharmaceutical drug development services of pharmaceutical products intended for the treatment of metabolic disorders, namely, obesity and atherosclerosis; pharmaceutical drug development services of pharmaceutical products intended for the treatment of cardiovascular disorders, namely, hypertension, congestive heart failure, myocardial infarction, angina and vascular diseases; pharmaceutical drug development services of pharmaceutical products intended for the treatment of renal disorders, namely, acute and chronic renal failure and urinary disorders affecting renal conservation of water; pharmaceutical drug development services of pharmaceutical products intended for the treatment of central nervous system disorders, namely, analgesia, anesthesia, hypnotics, sedatives, anxiety, psychosis, depression, mania, epilepsies, migraine, neurodegeneration, and drug addiction; pharmaceutical drug development services of pharmaceutical products intended for the treatment of inflammatory disorders, namely, asthma, gout, inflammatory bowel disease, and rheumatoid arthritis; pharmaceutical drug development services of pharmaceutical products intended for the treatment of gastrointestinal disorders, namely, ulcers, emesis, diarrhea, and irritable bowel syndrome; pharmaceutical drug development services of pharmaceutical products intended for the treatment of hormonal disorders affecting the thyroid, estrogens, progestins, androgens, glucocorticoids, insulin and glucose regulation; pharmaceutical drug development services of pharmaceutical products intended for the treatment of calcification and bone turnover; and pharmaceutical drug development services of pharmaceutical products intended for the treatment of dermatological and opthalmological disorders
Publicações
Histórico de despachos e eventos da marca no USPTO.
50 publicações encontradas
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
03/10/2019
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
03/10/2019
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
03/10/2019
E89R
TEAS SECTION 8 & 9 RECEIVED
23/08/2019
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
25/08/2018
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
22/01/2016
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
25/09/2015
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
25/09/2015
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
25/09/2015
E815
TEAS SECTION 8 & 15 RECEIVED
21/08/2015
R.PR
REGISTERED-PRINCIPAL REGISTER
25/08/2009
REGV
LAW OFFICE REGISTRATION REVIEW COMPLETED
21/07/2009
ALIE
ASSIGNED TO LIE
21/07/2009
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
13/07/2009
SUPC
STATEMENT OF USE PROCESSING COMPLETE
09/07/2009
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
09/07/2009
EISU
TEAS STATEMENT OF USE RECEIVED
15/06/2009
IUAF
USE AMENDMENT FILED
13/06/2009
EX5G
SOU EXTENSION 5 GRANTED
10/12/2008
EXT5
SOU EXTENSION 5 FILED
10/12/2008
EEXT
SOU TEAS EXTENSION RECEIVED
10/12/2008
EX4G
SOU EXTENSION 4 GRANTED
12/06/2008
EXT4
SOU EXTENSION 4 FILED
12/06/2008
EEXT
SOU TEAS EXTENSION RECEIVED
12/06/2008
DOCK
ASSIGNED TO EXAMINER
08/01/2008
EX3G
SOU EXTENSION 3 GRANTED
13/12/2007
EXT3
SOU EXTENSION 3 FILED
13/12/2007
EEXT
SOU TEAS EXTENSION RECEIVED
13/12/2007
EX2G
SOU EXTENSION 2 GRANTED
13/06/2007
EXT2
SOU EXTENSION 2 FILED
13/06/2007
EEXT
SOU TEAS EXTENSION RECEIVED
13/06/2007
EX1G
SOU EXTENSION 1 GRANTED
13/12/2006
EXT1
SOU EXTENSION 1 FILED
13/12/2006
EEXT
SOU TEAS EXTENSION RECEIVED
13/12/2006
NOAM
NOA MAILED - SOU REQUIRED FROM APPLICANT
13/06/2006
PUBO
PUBLISHED FOR OPPOSITION
21/03/2006
NPUB
NOTICE OF PUBLICATION
01/03/2006
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
03/02/2006
ALIE
ASSIGNED TO LIE
02/12/2005
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
29/11/2005
GNEA
EXAMINERS AMENDMENT E-MAILED
29/11/2005
CNEA
EXAMINERS AMENDMENT -WRITTEN
29/11/2005
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
23/11/2005
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
17/11/2005
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
17/11/2005
GEAP
EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
25/10/2005
CPEA
EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
25/10/2005
DOCK
ASSIGNED TO EXAMINER
22/10/2005
NWAP
NEW APPLICATION ENTERED
01/04/2005
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace INDUS PHARMACEUTICALS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.